Mesenchymal Stem Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property | Value | [1]
|----------|-------| [2]
| Treatment Name | Mesenchymal Stem Cell (MSC) Therapy | [3]
| Cell Type | Mesenchymal Stromal Cells | [4]
| Target Indications | Parkinson's Disease, Alzheimer's Disease, ALS, Multiple System Atrophy |
| Mechanism | Immunomodulation, neurotrophic factor secretion, mitochondrial transfer |
| Route of Administration | Intravenous, intrathecal, stereotactic injection |
| Clinical Stage | Phase 1/2 clinical trials |
Mesenchymal stem cells (MSCs) are adult stem cells with powerful immunomodulatory and neurotrophic properties that make them attractive candidates for cell therapy in neurodegenerative diseases.
MSCs exert therapeutic effects through multiple mechanisms:
Phase 1/2 Trials (NCT00911326, NCT01827180): MSC transplantation
** ongoing Phase 2**: Optimizing cell dose and delivery
Phase 1 Trials: MSC infusion in AD patients
Phase 2 Trials: Ongoing in mild-to-moderate AD
Phase 1/2 Trials (NCT01348451): MSC-NT3 delivery
NurOwn®: Autologous MSC therapy (BrainStorm Cell Therapeutics)
| Route | Advantages | Disadvantages |
|---|---|---|
| Intravenous | Minimally invasive, systemic effect | Limited CNS penetration |
| Intrathecal | Direct CSF delivery | Invasive, requires lumbar puncture |
| Stereotactic | Precise brain targeting | Most invasive |
| Intra-arterial | High CNS exposure | Risk of emboli |
MSC therapy may be combined with:
The study of Mesenchymal Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Autologous mesenchymal stem cell therapy for Parkinson's disease: a 36-month follow-up. Parkinsonism Relat Disord. 2016. ↩︎
MSC therapy in Alzheimer's disease: safety and cognitive effects. Stem Cells Transl Med. 2015. ↩︎
NurOwn, autologous mesenchymal stem cells, in ALS: phase 3 results. Nat Med. 2020. ↩︎
Mesenchymal stem cell-derived exosomes in neurodegenerative diseases. Prog Neurobiol. 2022. ↩︎